Skip to main content
Top
Published in: Journal of Cancer Survivorship 3/2021

01-06-2021 | Breast Cancer

Prevalence, pattern, and probability for goals of care discussions among women diagnosed with metastatic breast cancer

Authors: Rachel L. Brazee, Susan M. Sereika, Margaret Q. Rosenzweig

Published in: Journal of Cancer Survivorship | Issue 3/2021

Login to get access

Abstract

Purpose

High quality advanced cancer care includes goals of care (GOC) discussions and should be tailored according to clinical diagnosis, patient characteristics, and in concordance with patient’s goals. Metastatic breast cancer (MBC) and treatment has heterogeneity according to subtype which makes the timing of initiating and continuing GOC discussions challenging. With an ever-increasing array of therapy, women with advanced stage disease are unique survivors in that they receive relatively aggressive cancer care to not only palliative symptoms but extend survival time. It is the purpose of this paper to explore the prevalence, pattern, and likelihood of having a GOC discussion according to key tumor, demographic, social, and clinical factors.

Methods

A single-institution retrospective chart review of women deceased from MBC between November 2016 and November 2019 with double verification chart review was completed. Data were analyzed with descriptive, correlative, and comparative statistics.

Results

Total sample was N=167 women, with 14.4% (n=24) Black and 85.6% (n=143) White. Mean age was 55.3 years (SD 11.73). Overall, MBC survival was 3.12 years (SD 3.31), White women 41.2 (3.4 years) months, and Black women 19 (1.6 years) months. A total of 87.4% (n=146) participated in one or more GOC discussions. GOC discussions were more likely among those who were referred to palliative care (p<0.001) and social work (p=0.035) services. Of the GOC discussions, only 29.3% were conducted by the primary oncologist. Black women were more likely to have GOC discussion near death.

Conclusion and implications

Advanced stage cancers are treated, at times relatively aggressively, to extend survival time instead of merely offering palliation. This new paradigm of survivorship requires thoughtful integration of GOC conversations. Describing the current status of GOC discussions among a cohort of women deceased from MBC highlights the patients most vulnerable to having a GOC discussion avoided or delayed. These identified vulnerabilities will indicate where targeted interventions can be implemented in the future.
Literature
5.
go back to reference Levit L, Balogh E, Nass S, Ganz PA. Delivering high-quality cancer care: charting a new course for a system in crisis committee on improving the quality of cancer care: addressing the challenges of an aging population board on health care services.; 2013. http://www.nap.edu. Accessed October 27, 2020. Levit L, Balogh E, Nass S, Ganz PA. Delivering high-quality cancer care: charting a new course for a system in crisis committee on improving the quality of cancer care: addressing the challenges of an aging population board on health care services.; 2013. http://​www.​nap.​edu. Accessed October 27, 2020.
Metadata
Title
Prevalence, pattern, and probability for goals of care discussions among women diagnosed with metastatic breast cancer
Authors
Rachel L. Brazee
Susan M. Sereika
Margaret Q. Rosenzweig
Publication date
01-06-2021
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 3/2021
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-021-01022-w

Other articles of this Issue 3/2021

Journal of Cancer Survivorship 3/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine